All lobbying filings

WILLIAMS AND JENSEN, PLLC

WILLIAMS AND JENSEN, PLLC filed a Q2 report for PLASMA PROTEIN THERAPEUTICS ASSOCIATION on July 18, 2025, reporting $50,000 in lobbying income.

Lobbying for PLASMA PROTEIN THERAPEUTICS ASSOCIATION

All filings by WILLIAMS AND JENSEN, PLLC · Everything PLASMA PROTEIN THERAPEUTICS ASSOCIATION has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 18, 2025

Income

$50,000

What the client paid this registrant for the period.

Client based in

Maryland

Official filing document

Lobbyists on this filing 5

LAURA M SIMMONS

Previously held: Advisor, Office of Legislative Affairs, Dept of Homeland Security
CHRISTOPHER E. WILCOX

Previously held: LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
JEANNE HAGGERTY

Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
KURT SCHRADER Former member of Congress

Previously held: Former Member of Congress
ROBERT BUTORA New on this filing

Previously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Medicare/Medicaid

Matters related to access to and pricing of plasma derived products and matters affecting the Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Health Issues

Matters affecting plasma donation and potential plasma shortages. Issues related to PAHPA.

Taxation/Internal Revenue Code

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Bills named in this filing 1

H.R. 1
One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.